Impact of allopurinol on risk of myocardial infarction (Q39033643)

8 September 2017

Impact of allopurinol on risk of myocardial infarction (English)

1 reference

8 September 2017

1 reference

ChEBI release 2020-05-28

ChEBI ID

40279

myocardial infarction

1 reference

P Richette

7

0 references

Lamiae Grimaldi-Bensouda

object named as

L Grimaldi-Bensouda

1

0 references

author name string

A Alpérovitch

2

1 reference

8 September 2017

E Aubrun

3

1 reference

8 September 2017

N Danchin

4

1 reference

8 September 2017

M Rossignol

5

1 reference

8 September 2017

L Abenhaim

6

1 reference

8 September 2017

PGRx MI Group

8

1 reference

8 September 2017

language of work or name

English

0 references

publication date

6 January 2014

1 reference

Annals of the Rheumatic Diseases

8 September 2017

1 reference

8 September 2017

74

1 reference

8 September 2017

836-842

1 reference

8 September 2017

5

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202972

8 September 2017

1 reference

Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007-2008.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202972

Uric acid: A marker of increased cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202972

Gout and the risk of acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202972

Serum uric acid level and risk for peripheral arterial disease: analysis of data from the multiple risk factor intervention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202972

Hyperuricemia and untreated gout are poor prognostic markers among those with a recent acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202972

Long-term cardiovascular mortality among middle-aged men with gout

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202972

Are either or both hyperuricemia and xanthine oxidase directly toxic to the vasculature? A critical appraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202972

Hyperuricaemia and gout: state of the art and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202972

Elevated serum uric acid is associated with high circulating inflammatory cytokines in the population-based Colaus study

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202972

Tophaceous gout and high level of hyperuricaemia are both associated with increased risk of mortality in patients with gout.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202972

EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202972

Colchicine for the treatment of gout

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202972

Colchicine use is associated with decreased prevalence of myocardial infarction in patients with gout.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202972

Risk of ST versus non-ST elevation myocardial infarction associated with non-steroidal anti-inflammatory drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202972

Agreement between patients' self-report and physicians' prescriptions on nonsteroidal anti-inflammatory drugs and other drugs used in musculoskeletal disorders: the international Pharmacoepidemiologic General Research eXtension database.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202972

Allopurinol and mortality in hyperuricaemic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202972

Xanthine oxidase inhibition for the treatment of cardiovascular disease: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202972

Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202972

Allopurinol as a cardiovascular drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202972

Gout, allopurinol use, and heart failure outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202972

Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202972

Uric acid, heart failure survival, and the impact of xanthine oxidase inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202972

Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202972

The impact of serum uric acid on cardiovascular outcomes in the LIFE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202972

High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202972

Uric acid-lowering treatment with benzbromarone in patients with heart failure: a double-blind placebo-controlled crossover preliminary study

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202972

Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202972

Gout epidemiology: results from the UK General Practice Research Database, 1990-1999.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202972

Suboptimal physician adherence to quality indicators for the management of gout and asymptomatic hyperuricaemia: results from the UK General Practice Research Database (GPRD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202972

Xanthine oxidase inhibition with febuxostat attenuates systolic overload-induced left ventricular hypertrophy and dysfunction in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202972

Febuxostat compared with allopurinol in patients with hyperuricemia and gout

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202972

The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202972

Guillain-Barre syndrome, influenzalike illnesses, and influenza vaccination during seasons with and without circulating A/H1N1 viruses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202972

High-dose allopurinol reduces left ventricular mass in patients with ischemic heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202972

10.1136/ANNRHEUMDIS-2012-202972

21 January 2018

Identifiers

DOI

1 reference

8 September 2017

1 reference